InMed Pharmaceuticals Inc.
No enriched coverage for $INM in the last 7 days.
ADAR1 Capital Management, LLC purchased 91,101 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.30 ($1.29–$1.30, $0.12M total) across 3 trades over 2026-09-14 to 2026-09-16. Filed jointly with Schneeberger Daniel (10% owner).
InMed Pharmaceuticals (INM) reported a net loss of $12.9M for FY2026, up from $8.2M in FY2025. The company is pursuing a merger with Mentari Therapeutics, expected to close by year-end, with Mentari raising $490M in pre-closing financing. InMed's legacy programs, including INM-901, INM-089, and INM-755, are being pursued for strategic opportunities. The company had $2.2M in cash as of June 30, 2026.
InMed Pharmaceuticals reported a net loss of $12.6M for FY 2026, with cash reserves expected to last until Q3 2026. The company ceased its revenue operations and is focusing on R&D, pending a merger or new funding.
Recent INM coverage spans insider activity, mergers & acquisitions and earnings.
In the last 30 days, INM insiders filed 3 SEC Form 4 transactions — 3 purchases ($118K) and no sales. The most active reporter was ADAR1 Capital Management, LLC with 3 filings.
Minor increase in insider ownership; unlikely to move price materially.
Merger creates a larger migraine‑focused company; share price may react to deal completion risk and financing terms.
The loss and operational shutdown suggest short-term pressure on the stock, while merger/funding prospects could provide upside if materialized.
Capital raise tied to the merger increases funding visibility for InMed’s combined entity and may support near-term risk appetite for the deal.
The financing and merger mechanics are likely to support near-term risk sentiment for INM, but dilution and deal-close timing remain key risks.
AlphAI scores every news story that mentions INM with an AI model for sentiment and relevance, and aggregates insider trades from InMed Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ADAR1 Capital Management, LLC purchased 91,101 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.30 ($1.29–$1.30, $0.12M total) across 3 trades over 2026-09-14 to 2026-09-16. Filed jointly with Schneeberger Daniel (10% owner).
1 min readInMed Pharmaceuticals (INM) reported a net loss of $12.9M for FY2026, up from $8.2M in FY2025. The company is pursuing a merger with Mentari Therapeutics, expected to close by year-end, with Mentari raising $490M in pre-closing financing. InMed's legacy programs, including INM-901, INM-089, and INM-755, are being pursued for strategic opportunities. The company had $2.2M in cash as of June 30, 2026.
2 min readInMed Pharmaceuticals reported a net loss of $12.6M for FY 2026, with cash reserves expected to last until Q3 2026. The company ceased its revenue operations and is focusing on R&D, pending a merger or new funding.
1 min readMentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.
4 min readInMed Pharmaceuticals (INM) rose in pre-market after merger partner Mentari Therapeutics announced a $200 million private placement of common stock and pre-funded warrants. Mentari said the funds extend its runway to 2029 and support Phase 2a readouts for PACAP programs, including MT-002. The all-stock merger with InMed is expected to close in 2H 2026.
3 min readVivo Opportunity, LLC purchased 20,546 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $1.55 across 6 trades over 2026-07-14 to 2026-07-16.
1 min readInMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001728328 0001728328 2026-07-06 2026-07-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readInMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.
3 min readVivo Opportunity, LLC purchased 6,551 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.55 ($1.54–$1.55) across 6 trades over 2026-06-30 to 2026-07-02.
2 min readVivo Opportunity, LLC purchased 249,227 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.57 ($1.52–$1.69, $0.39M total) across 18 trades over 2026-05-20 to 2026-06-08.
2 min read
